Apatinib Suppresses Angiogenesis inside Intrahepatic Cholangiocarcinoma through Regulating the General Endothelial Progress Factor Receptor-2/Signal Transducer as well as Activator involving Transcribing Factor 3/Hypoxia Inducible Aspect One Subunit Alpha Signaling Axis.